188 related articles for article (PubMed ID: 33907234)
1. High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens.
Cheng LY; Haydu LE; Song P; Nie J; Tetzlaff MT; Kwong LN; Gershenwald JE; Davies MA; Zhang DY
Sci Rep; 2021 Apr; 11(1):9043. PubMed ID: 33907234
[TBL] [Abstract][Full Text] [Related]
2. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.
Ihle MA; Fassunke J; König K; Grünewald I; Schlaak M; Kreuzberg N; Tietze L; Schildhaus HU; Büttner R; Merkelbach-Bruse S
BMC Cancer; 2014 Jan; 14():13. PubMed ID: 24410877
[TBL] [Abstract][Full Text] [Related]
3. Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays.
Qu K; Pan Q; Zhang X; Rodriguez L; Zhang K; Li H; Ho A; Sanders H; Sferruzza A; Cheng SM; Nguyen D; Jones D; Waldman F
J Mol Diagn; 2013 Nov; 15(6):790-5. PubMed ID: 23994118
[TBL] [Abstract][Full Text] [Related]
4. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
[TBL] [Abstract][Full Text] [Related]
5. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.
Anderson S; Bloom KJ; Vallera DU; Rueschoff J; Meldrum C; Schilling R; Kovach B; Lee JR; Ochoa P; Langland R; Halait H; Lawrence HJ; Dugan MC
Arch Pathol Lab Med; 2012 Nov; 136(11):1385-91. PubMed ID: 22332713
[TBL] [Abstract][Full Text] [Related]
6. A HRM assay for identification of low level BRAF V600E and V600K mutations using the CADMA principle in FFPE specimens.
Huebner C; Weber R; Lloydd R
Pathology; 2017 Dec; 49(7):776-783. PubMed ID: 29100713
[TBL] [Abstract][Full Text] [Related]
7. Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes.
Jurkowska M; Gos A; Ptaszyński K; Michej W; Tysarowski A; Zub R; Siedlecki JA; Rutkowski P
Int J Clin Exp Pathol; 2015; 8(7):8487-93. PubMed ID: 26339422
[TBL] [Abstract][Full Text] [Related]
8. Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma.
Melchior L; Grauslund M; Bellosillo B; Montagut C; Torres E; Moragón E; Micalessi I; Frans J; Noten V; Bourgain C; Vriesema R; van der Geize R; Cokelaere K; Vercooren N; Crul K; Rüdiger T; Buchmüller D; Reijans M; Jans C
Exp Mol Pathol; 2015 Dec; 99(3):485-91. PubMed ID: 26407762
[TBL] [Abstract][Full Text] [Related]
9. A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma.
Richter A; Grieu F; Carrello A; Amanuel B; Namdarian K; Rynska A; Lucas A; Michael V; Bell A; Fox SB; Hewitt CA; Do H; McArthur GA; Wong SQ; Dobrovic A; Iacopetta B
Sci Rep; 2013; 3():1659. PubMed ID: 23584600
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas.
Lade-Keller J; Rømer KM; Guldberg P; Riber-Hansen R; Hansen LL; Steiniche T; Hager H; Kristensen LS
J Mol Diagn; 2013 Jan; 15(1):70-80. PubMed ID: 23159593
[TBL] [Abstract][Full Text] [Related]
11. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.
Fisher KE; Cohen C; Siddiqui MT; Palma JF; Lipford EH; Longshore JW
Hum Pathol; 2014 Nov; 45(11):2281-93. PubMed ID: 25228337
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma.
Franczak C; Salleron J; Dubois C; Filhine-Trésarrieu P; Leroux A; Merlin JL; Harlé A
Mol Diagn Ther; 2017 Apr; 21(2):209-216. PubMed ID: 28130756
[TBL] [Abstract][Full Text] [Related]
13. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.
Halait H; Demartin K; Shah S; Soviero S; Langland R; Cheng S; Hillman G; Wu L; Lawrence HJ
Diagn Mol Pathol; 2012 Mar; 21(1):1-8. PubMed ID: 22306669
[TBL] [Abstract][Full Text] [Related]
14. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
Bisschop C; Ter Elst A; Bosman LJ; Platteel I; Jalving M; van den Berg A; Diepstra A; van Hemel B; Diercks GFH; Hospers GAP; Schuuring E
Melanoma Res; 2018 Apr; 28(2):96-104. PubMed ID: 29232304
[TBL] [Abstract][Full Text] [Related]
15. Comparison of droplet digital PCR and direct Sanger sequencing for the detection of the BRAF
Wang Z; Sun K; Jing C; Cao H; Ma R; Wu J
J Clin Lab Anal; 2019 Jul; 33(6):e22902. PubMed ID: 31021028
[TBL] [Abstract][Full Text] [Related]
16. BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay.
Tatsuno M; Shioda Y; Iwafuchi H; Yamazaki S; Iijima K; Takahashi C; Ono H; Uchida K; Okamura O; Matubayashi M; Okuyama T; Matsumoto K; Yoshioka T; Nakazawa A
Diagn Pathol; 2016 Apr; 11():39. PubMed ID: 27094161
[TBL] [Abstract][Full Text] [Related]
17. Automated universal BRAF state detection within the activation segment in skin metastases by pyrosequencing-based assay U-BRAF(V600).
Skorokhod A; Helmbold P; Brors B; Schirmacher P; Enk A; Penzel R
PLoS One; 2013; 8(3):e59221. PubMed ID: 23555633
[TBL] [Abstract][Full Text] [Related]
18. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system.
Janku F; Claes B; Huang HJ; Falchook GS; Devogelaere B; Kockx M; Bempt IV; Reijans M; Naing A; Fu S; Piha-Paul SA; Hong DS; Holley VR; Tsimberidou AM; Stepanek VM; Patel SP; Kopetz ES; Subbiah V; Wheler JJ; Zinner RG; Karp DD; Luthra R; Roy-Chowdhuri S; Sablon E; Meric-Bernstam F; Maertens G; Kurzrock R
Oncotarget; 2015 Sep; 6(29):26886-94. PubMed ID: 26330075
[TBL] [Abstract][Full Text] [Related]
19. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.
Boursault L; Haddad V; Vergier B; Cappellen D; Verdon S; Bellocq JP; Jouary T; Merlio JP
PLoS One; 2013; 8(8):e70826. PubMed ID: 23976959
[TBL] [Abstract][Full Text] [Related]
20. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.
Huang WK; Kuo TT; Wu CE; Cheng HY; Hsieh CH; Hsieh JJ; Shen YC; Hou MM; Hsu T; Chang JW
Asia Pac J Clin Oncol; 2016 Dec; 12(4):403-408. PubMed ID: 27488807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]